ReVance Therapeutics Obtains $8,000,000 New Funding

  • Feed Type
  • Date
    11/18/2008
  • Company Name
    ReVance Therapeutics
  • Mailing Address
    7555 Gateway Boulevard Newark, CA 94560
  • Company Description
    Revance is developing its lead compound, a topical botulinum toxin based on its cutting-edge drug delivery platforms and low molecular weight botulinum toxin. This product leverages Revance’s platform technologies to enhance patient tolerability of botulinum toxin. The technology is being designed and tested to eliminate the need for needle injections, while permitting a safe, local, targeted, and painless approach to treat facial aesthetics and hyperhidrosis.
  • Website
    http://www.revance.com
  • Transaction Type
    Debt
  • Transaction Amount
    $8,000,000
  • Transaction Round
    Undisclosed
  • Proceeds Purposes
    Proceeds purposes were not disclosed.
  • M&A Terms
  • Venture Investor
    Leader Ventures
  • Venture Investor
    Horizon Technology Finance

By posting a comment, you agree to our terms and conditions.